NikolaiAlexandrovichPodoltsevMD

PubMed

• 73 citations
  Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
  Alexander E Perl, Richard A Larson, Nikolai A Podoltsev, Stephen Strickland, Eunice S Wang
  Blood. 2022-06-09
• 14 citations
  The Impact of Phlebotomy and Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients with Polycythemia Vera
  Nikolai A. Podoltsev, Mengxin Zhu, Amer M. Zeidan, Rong Wang, Xiaoyi Wang
  Blood Advances. 2018-10-23
• 6 citations
  Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
  Rong Wang, Rory M Shallis, Jessica M Stempel, Scott F Huntington, Amer M Zeidan
  Blood Advances. 2023-03-14

Abstracts/Posters

• Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Phase 1b Study of the Epichaperome Inhibitor PU-H71 Administered Orally with Ruxolitinib Continuation for the Treatment of Patients with Myelofibrosis
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Populati...
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Populatio...
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United State...
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neopl...
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Blinatumomab
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The VITAL Trial: Phase II Trial of Vosaroxin and Infusional Cytarabine for Frontline Treatment of acute Myeloid LeukemiaClinically Relevant Abstract
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
  Nikolai A. Podoltsev, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and ... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018